Dual Effects of NV-CoV-2 Biomimetic Polymer: An Antiviral regimen against COVID-19
Keyword(s):
Remdesivir (RDV) is the only antiviral drug so far approved for COVID-19 therapy by the FDA. However its efficacy is limited in vivo due to its low stability in presence of plasma. This paper compared the stability of RDV encapsulated with our platform technology based polymer NV-387 (NV-CoV-2), in presence of plasma in vitro and in vivo . Furthermore, a non-clinical pharmacology studies of NV-CoV-2 (Polymer) and NV-CoV-2-R (Polymer encapsulated Remdesivir ) in both NL-63 infected and uninfected rats were done. In an in vitro cell culture model experiment, antiviral activity of NV-CoV-2 and NV-CoV-2-R are also compared with RDV.
Keyword(s):
2013 ◽
Vol 45
(4)
◽
pp. 325
◽
Keyword(s):
2019 ◽
Vol 64
(2)
◽
pp. 112-123
◽
2011 ◽
Vol 113
(6)
◽
pp. 1468-1475
◽
2015 ◽
Vol 53
(1)
◽
pp. 66-72
◽
1999 ◽
Vol 64
(5)
◽
pp. 925-928
◽